SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr
®
system and provider of N
x
Clinical™, the leading software solution for visualization, interpretation and reporting of genomic data, today announced the appointment of Aleks Rajkovic, MD, PhD, to its board of directors.
Dr. Rajkovic is currently the Chief Genomics Officer at the University of California, San Francisco (UCSF), a Stuart Lindsay Distinguished Professor in Experimental Pathology, and Medical Director and Chief of the Center for Genetic and Genomic Medicine at UCSF Health. Prior to arriving to UCSF, he was the Chief of Medical and Laboratory Genetics at the University of Pittsburgh Medical Center where he oversaw Pittsburgh’s cytogenomic, molecular genomic and pregnancy screening laboratories as well as adult/cancer and prenatal genetic clinical services. He has been the Principal Investigator on NIH grants that studied various aspects of reproductive genomics, women’s health, and population genetic screening, and has published more than 150 original peer-reviewed articles in leading medical journals, including
The New England Journal of Medicine
,
JAMA
, and
Nature Genetics
.
“We are honored to have Dr. Rajkovic joining the board of directors,” said Erik Holmlin, PhD, president and chief executive officer at Bionano. “He brings rich expertise across genomic disciplines and a deep understanding of the current and future needs of academic medical centers. His depth of experience in reproductive health, including human fertility and prenatal genetics, adds to the clinical expertise of our board. I’m excited to work closely with Dr. Rajkovic as we seek to expand the capabilities and adoption of OGM for cytogenetics and translational research.”
“I am pleased to be joining Bionano’s board at this stage in the company’s development,” commented Dr. Rajkovic. “I believe optical genome mapping can have significant impact on patient management and research into novel genome-based biomarkers that could be therapeutically relevant and useful for patient recruitment and stratification.”
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit
www.bionanogenomics.com
,
www.lineagen.com
or
www.biodiscovery.com
.
Forward-Looking Statements of Bionano Genomics
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ability expand the capabilities and adoption of OGM, including Dr. Rajkovic’s contributions, the ability for OGM to significantly impact patient management and research into novel genome-based biomarkers, and Dr. Rajkovic’s ability to add to the clinical expertise of Bionano’s board of directors.. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape, including the introduction of competitive technologies or improvements in existing technologies; failure of OGM to perform in the future as observed in prior studies; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2021 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
[email protected]
Investor Relations:
Amy Conrad
Juniper Point
+1 (858) 366-3243
[email protected]
Media Relations:
Michael Sullivan
Seismic
+1 (503) 799-7520
[email protected]
